Management

CEO since 2020. 

Born: 1976

Education and experience: Morten Henneveld has extensive international and medical device experience having worked as Director, Commercial Excellence for Coloplast during 2008-2012, including a period working in the USA, and then, based in Malmö, working as Managing Director, Sweden and Regional Vice President, Nordics for Biomet and subsequently Vice President, EMEA Spine for Zimmer Biomet from 2012-2016. Previously Morten was Senior Vice President, Business Transformation and Strategy for GN Group.

Other current roles: Advisory Board Member at SIME Clinical AI.

Holdings in OssDsign: 17 500 shares.

CFO since 2020.

Born: 1963

Education and experience: MBA, focused on Strategy/Finance from AGSM (Australian Graduate School of Management). Anders has many years of experience in senior positions that span over multiple industries which include production as well as service companies. Anders is an experienced Chief Financial Officer with a demonstrated history from a diverse range of industries such as digital sustainability, retail, lighting and electronics manufacturing, pharmaceuticals, banking, management consulting and software development in Sweden and internationally and has with good merits driven finance departments.

Other current roles: -

Holdings in OssDsign: -

VP Technical Operations since 2021 and previously Director of Technical Operations since 2018 and  Director of Development since 2016. 

Born: 1973

Education and experience: PhD in Inorganic Chemistry from Uppsala University. M.Sc. in Chemistry from Uppsala University. Executive MBA from Mgruppen Svenska Managementgruppen AB. Kajsa Björklund has worked in the life science industry since 2001 and has held positions as line manager, project manager and consultant, with focus on MedTech and products within in vitro-diagnostics. Björklund has comprehensive experience in product development, project management, design transfer and quality work. Björklund’s role as Director Technical Operations includes responsibility for production, product supply, manufacturing technology and product development.

Other current roles: -

Holdings in OssDsign: 9 000 shares and 24 466 subscription options.

Director of Quality Assurance & Regulatory Affairs since 2017. 

Born: 1969

Education and experience: Master's in natural sciences and mathematics from Uppsala University. Malin Kylberg has worked with quality assurance in the life sciences industry for the last 20 years and has comprehensive experience from quality work and regulatory issues in both pharmaceutical and medtech companies, including from senior roles with responsibilities such as being the responsible individual appointed by the Swedish Medical Products Agency.

Other current roles: -

Holdings in OssDsign: 4 000 shares and 24 466 subscription options.

Director of Clinical Engineering since 2016. 

Born: 1979

Education and experience: Master of Science in Computer Technology Engineering at Royal Institute of Technology. PhD from Karolinska Institutet. Ulrik Birgersson has over fifteen years' experience from the life science industry and has held various roles, with a particular focus on pre-clinical and clinical studies and trial applications, including administration of applications and reporting to and communication with medical agencies such as, for example, the American pharmaceutical authority, the FDA. Birgersson was also involved in the work prior to the PMA approval that SciBase received in 2017 and was then responsible for managing pre-IDE and pre-PMA discussions with the FDA.

Other current roles: CEO of Data Vigilence Consulting AB. Chairman of the Board at Stockholm City Triathlon.

Holdings in OssDsign: 1 600 shares 24 466 subscription options.

VP of Commercial Operations since 2016. 

Born: 1974

Education and experience: Bachelor of Science in pharmacology from Sheffield University (Sheffield, United Kingdom). Rick Thomas has 22 years' experience from commercial roles in the pharmaceutical and medtech industries, initially in large organisations such as Medtronic and subsequently with companies in the start-up phase. Thomas was a member of the management group of Apatech, a British company successfully sold to Baxter for around USD 330 million in March 2010.

Other current roles: Board member of RedMed Consulting Ltd.

Holdings in OssDsign: 6 300 shares 85 632 subscription options.